Idarubicin Accord (Idarubicin Hydrochloride)

Idarubicin intercalates into DNA and blocks the activity of topoisomerase II, an enzyme required for DNA replication and transcription. This interference creates irreversible DNA strand breaks, leading to apoptosis of rapidly dividing cancer cells, especially leukemic blasts.

The specific dose of idarubicin is determined by the prescribing oncologist based on disease characteristics, patient weight, renal and hepatic function, and treatment protocol. Dosing regimens are individualized and should follow established clinical guidelines.

Idarubicin is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and is excreted in breast milk, posing a risk of fetal or neonatal toxicity. Women of child‑bearing potential should use effective contraception during treatment and for a defined period afterward.

To place an order, submit an enquiry on the Idarubicin Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Idarubicin is a more lipophilic anthracycline than daunorubicin, allowing greater cellular uptake and potentially higher antileukemic activity. Clinically, idarubicin is often preferred for certain AML protocols because it may achieve remission with fewer infusion‑related toxicities, although both agents share similar cardiotoxic risk profiles.

Idarubicin Accord must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The solution should be kept in its original container until use, and any unused portion must be discarded according to local hazardous‑drug disposal regulations.

Idarubicin Accord is administered intravenously by a qualified healthcare professional, typically as a short infusion over several minutes. The exact infusion rate and schedule are defined by the treating physician and depend on the chemotherapy protocol being followed.

The most serious risks include cardiotoxicity (which can lead to heart failure), severe myelosuppression resulting in neutropenia or infection, life‑threatening hemorrhage, and rare but severe hypersensitivity reactions. Continuous monitoring of cardiac function and blood counts is essential throughout treatment.

Idarubicin is contraindicated in patients with known hypersensitivity to anthracyclines, existing uncontrolled cardiac disease, severe hepatic impairment, or active uncontrolled infections. It should also be avoided in pregnant or breastfeeding women and in individuals lacking adequate organ function to safely metabolize the drug.